Free fatty acid receptor 3 is a key target of short chain fatty acid: What is the impact on the sympathetic nervous system?

Eduardo Javier López Soto1,*, Luisina Ongaro Gambino2, and Emilio Román Mustafá1

1Laboratory of Electrophysiology; Multidisciplinary Institute of Cell Biology (IMBICE - CICPBA/CONICET); Buenos Aires, Argentina; 2Laboratory of Neuroendocrinology; Multidisciplinary Institute of Cell Biology (IMBICE - CICPBA/CONICET); Buenos Aires, Argentina

Keywords: Short chain fatty acids, N-type calcium channels, CaV2.2, FFA3, GPR41, FFA2, GPR43

Abbreviations: NS, nervous system; SCFAs, short chain fatty acids; GPCR, G-protein coupled receptor; FFA2, Free Fatty Acid Receptor 2; FFA3, Free Fatty Acid Receptor 3; NE, norepinephrine; NTCC, N-type calcium channel; BHB, β-hydroxybutyrate; VD, voltage dependent; VI, voltage independent; PTX, pertussis toxin.

*Correspondence to: Eduardo Javier López Soto; Email: jlopezsoto@imbice.gov.ar

Submitted: 04/17/2014
Accepted: 04/21/2014

Citation: López Soto EJ, Gambino LO, Mustafá ER. Free fatty acid receptor 3 is a key target of short chain fatty acid: What is the impact on the sympathetic nervous system?. Channels 2014; 8:1 - 0; PMID: 24762451; http://dx.doi.org/10.4161/chan.28956

Nervous system (NS) activity participates in metabolic homeostasis by detecting peripheral signal molecules derived from food intake and energy balance. High quality diets are thought to include fiber-rich foods like whole grain rice, breads, cereals, and grains. Several studies have associated high consumption of fiber-enriched diets with a reduced risk of diabetes, obesity, and gastrointestinal disorders. In the lower intestine, anaerobic fermentation of soluble fibers by microbiota produces short chain fatty acids (SCFAs), key energy molecules that have a recently identified leading role in the intestinal gluconeogenesis, promoting beneficial effects on glucose tolerance and insulin resistance1. SCFAs are also signaling molecules that bind to specific G-protein coupled receptors (GPCRs) named Free Fatty Acid Receptor 3 (FFA3 or GPR41) and 2 (FFA2 or GPR43). However, how SCFAs impact NS activity through their GPCRs is poorly understood.

Recently, some studies have demonstrated the presence of FFA2 and FFA3 in the sympathetic NS of rat, mouse and human2,3. Two studies have shown that FFA3 activation by SCFAs increases firing and norepinephrine (NE) release from sympathetic neurons5-4. However, the recent study from the Ikeda Laboratory2 revealed that activation of FFA3 by SCFAs impairs N-type calcium channel (NTCC) activity, this finding contradicts the idea of FFA3 activation leading to increased action potential evoked NE release. Here we will discuss the scope of the latter study and the putative physiological role of SCFAs and FFAs in the sympathetic NS.

FFAs Coupling to N-type Calcium Channels

Taking advantage of their electrophysiological expertise, Won et al. (2013) performed high quality whole-cell voltage clamp recordings in dissociated sympathetic neurons to assess the molecular coupling of FFAs to NTCC. In this setting, that offers extremely sensitive temporal resolution of native G protein mediated modulation of NTCC, they found that native NTCC currents are inhibited by heterologously expressed FFA2 and FFA3. Authors showed that FFAs activation is induced by either SCFAs (acetate or propionate) or the ketone body β-hydroxybutyrate (BHB), which was previously reported as an FFA antagonist.3 Thereby, they provided the first evidence that SCFAs and BHB negatively modulate NTCC by activating FFAs.

In order to characterize FFA2 and FFA3 mediated inhibition of NTCC, Won et al. (2013) recorded calcium currents evoked by a double-pulse voltage protocol5. This challenging protocol allows the physiologist to dissect the 2 GPCR signaling pathways involved in NTCC inhibition: the Gβ mediated pathway, which is impaired by strong depolarizing voltages, thereby producing a voltage dependent (VD) inhibition; and the Gα mediated pathway, which is resistant to changes in membrane voltage, resulting in a voltage independent
(VI) inhibition (for review, see ref. 6). Interestingly, the authors report that the facilitation ratio of NTCC, a measurement of the degree of VD inhibition, increased when FFA3 was activated and also increased but in a lesser extent when FFA2 was activated. Thus, they described that heterologously expressed FFA3 activated by SCFAs inhibits NTCC currents via a fully VD pathway while FFA2 has a partially VD mechanism of action. The authors could have compared the change in facilitation ratio to the total inhibition values to give a formal quantification of the VD and VI components of inhibition.

Understanding the contribution of VD and VI mechanisms to the total inhibition by FFA2 and FFA3 is important because each mechanism underlies completely different physiological impacts. VD inhibition is a membrane-delimited pathway that could display a transient disinhibition of NTCC during periods of strong neuronal electrical activity. In contrast, VI inhibition involves second messenger signaling and is not affected by changes in electrical activity. In the case of sympathetic neurons, the impact of VD and VI inhibition on presynaptic NTCC will be different depending if neurons belong to pre- or paravertebral ganglia since they have 2 distinct firing patterns. We suggest that whereas NTCC VD inhibition could be impaired to a greater degree during high frequency tonic action potentials in paravertebral neurons, it could persist in paravertebral neurons which display phasic firing properties.

**Make Bets: What’s FFAs Downstream?**

Signaling cascades downstream of GPCR activation define the global cellular effect of each agonist-receptor couple, and the G protein subtype confers the first level of specificity. Won et al. (2013) investigated the particular G proteins involved in the NTCC inhibition by heterologously expressed FFAs. In agreement with previous data, they found that FFA3 effect was completely mediated by Gi/o dimers released from activated pertussis toxin (PTX)-sensitive Gi/o protein, consistent with their finding that FFA3 inhibits NTCC in a VD manner. On the other hand, FFA2 inhibition of NTCC was partially occluded by PTX and the remaining fraction was VI. Based on previous reports, the authors hypothesized that the VI inhibition by FFA2 was mediated by its coupling to Gq, which involves lipid signaling such as PtdIns(4,5)P2 depletion from plasma membrane or arachidonic acid generation. To explore this pathway further, the authors could have incubated cells with a Gq-selective inhibitor (e.g., YM-254890) or transfected a dominant negative Gq mutant that prevents Gq binding to its targets.

**What Happens with Sympathetic FFAs?**

Based on the robust result obtained in heterologously expressed FFAs, Won et al. (2013) tested the SCFAs effect on native FFAs from sympathetic neurons. They found no effect of SCFAs on NTCC from superior cervical and stellate ganglia (paravertebral ganglia), but they did find a highly variable intra-assay inhibitory effect on major pelvic and celiac-superior mesenteric ganglia neurons (paravertebral ganglia) that correlates with the FFAs higher expression levels in these ganglia. Although both FFAs are detected in pre- and postsynaptic membranes by fine control of neurotransmitter release and electrical activity, respectively. Since NTCC rules NE release in the sympathetic NS, the activation of FFA3 could impair peripheral synaptic transmission by a presynaptic inhibitory mechanism. Strong evidence shows that propionate evokes action potentials and increases NE release in a FFA3 dependent manner in sympathetic neurons. Although these results seem to be opposite to the effect on NTCC, it is possible that these mechanisms occur in different ganglia. These studies support that FFA3 mediated sympathetic activation occurs in paravertebral sympathetic neurons where no NTCC inhibition by native FFA3 is detected, while FFA3 activation by propionate inhibits NTCCs in prevertebral sympathetic neurons, where
the effect on neuronal firing and/or NE release has not been tested.

Despite the fact that the physiological consequences of FFAs activation are not completely understood, studies such as the Won et al. (2013) contribute to our understanding of SCFAs as signaling molecules that act via FFA3 and modify sympathetic NS activity. Recent metabolic studies highlighted the benefits of soluble fiber by providing SCFAs energy substrates for intestinal gluconeogenesis, contributing to the management of energy balance and glucose metabolism. Additionally, it is well known that fiber-enriched diets promote intestinal motility by butyrate acting on enteric neurons. Here, we hypothesize acetate or propionate-induced FFA3 activation and further impact on NTCC activity in sympathetic neurons also contributes to this mechanism. SCFAs could target presynaptic terminals of prevertebral sympathetic neurons that innervate the lower intestine. Thereby, FFA3 activation could impair NE release, decreasing NE-mediated intestinal relaxation and finally contributing to increased intestinal motility.

In conclusion, Wong et al.’s (2013) study of the molecular relevance of FFA3 activation increases the understanding of effects provided by some healthy diets and suggests FFA3 as potential therapeutic targets to improve metabolic disorders such as obesity and diabetes.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Jesica Raingo and Cecilia Toro for critically reading our manuscript.

References

1. De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchamp A, Backhed F, Michieux G. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014; 156:84-96; PMID:24412651; http://dx.doi.org/10.1016/j.cell.2013.12.036
2. Won YJ, Lu VB, Puhl HL. 3rd, Ikeda SR. β-Hydroxybutyrate modulates N-type calcium channels in rat sympathetic neurons by acting as an agonist for the G-protein-coupled receptor FFA3, J. Neurosci 2013; 33:19314-25; PMID:23907011; http://dx.doi.org/10.1523/JNEUROSCI.3102-13.2013
3. Kimura I, Inoue D, Maeda T, Hara T, Ichimura A, Miyauuchi S, Kohayashi M, Hirasawa A, Tsujimoto G. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc Natl Acad Sci U S A 2011; 108:8030-5; PMID:21518883; http://dx.doi.org/10.1073/pnas.1016088108
4. Inoue D, Kimura I, Wakahayashi M, Tsumoto H, Ozawa K, Hara T, Takei Y, Hirasawa A, Ishihama Y, Tsujimoto G. Short-chain fatty acid receptor GPR41-mediated activation of sympathetic neurons involves synapsin 2b phosphorylation, FEBS Lett 2012; 586:1547-54; PMID:22673524; http://dx.doi.org/10.1016/j.febslet.2012.04.021
5. Ikeda SR. Double-pulse calcium channel current facilitation in adult rat sympathetic neurons. J Physiol 1991; 439:181-214; PMID:1654413
6. Zamponi GW, Currie KP. Regulation of Ca(V)2 calcium channels by G protein coupled receptors. Biochim Biophys Acta 2013; 1828:1629-43; PMID:23065655; http://dx.doi.org/10.1016/j.bbamem.2012.10.004
7. Johling P, Gibbins IH. Electrophysiological and morphological diversity of mouse sympathetic neurons. J Neurophysiol 1999; 82:2747-64; PMID:10561442
8. Lopez Soto EJ, Raingo J. A118G Mu Opioid Receptor polymorphism increases inhibitory effects on CaV2.2 channels. Neurosci Lett 2012; 523:190-4; PMID:22796651; http://dx.doi.org/10.1016/j.neulet.2012.06.074
9. Lin Z, Hau S, Edgerton J, Lipscombe D. Identification of functionally distinct isoforms of the N-type Ca2+ channel in rat sympathetic ganglia and brain. Neuron 1997; 18:153-66; PMID:9010213; http://dx.doi.org/10.1016/S0896-6273(01)80054-4
10. Lipscombe D, Allen SE, Toro C. Control of neuronal voltage-gated calcium ion channels from RNA to protein. Trends Neurosci 2013; 36:598-609; PMID:23907011; http://dx.doi.org/10.1016/j.tins.2013.06.008
11. Hirning LD, Fox AP, McCleskey EW, Oliveira BM, Thayer SA, Miller RJ, Tsen RW. Dominant role of N-type Ca2+ channels in evoked release of nor-epinephrine from sympathetic neurons. Science 1988; 239:57-61; PMID:2447674; http://dx.doi.org/10.1126/science.2447674
12. Soret R, Chevalier J, De Copper P, Poupeau G, Derkinderen P, Segain JP, Neunlist M. Short-chain fatty acids regulate the enteric neurons and control gastrointestinal motility in rats. Gastroenterology 2010;138:S177S282 PMID:20152834; http://dx.doi.org/10.1053/j. gastro.2010.01.053
13. Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care 2012; 15:474-9; PMID:22797568; http://dx.doi.org/10.1097/MCO.0b013e32835665fa